Real world study of the continuation of bevacizumab beyond disease progression after first‐line treatment containing bevacizumab in Chinese patients with advanced non‐small cell lung cancer

BACKGROUND: Bevacizumab (Bev) plus platinum‐based chemotherapy is a standard first‐line treatment option for advanced non‐squamous non‐small cell lung cancer (NS‐NSCLC). We evaluated the efficacy and safety of continuing Bev in Chinese patients with advanced NS‐NSCLC progression after first‐line tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Puyuan, Mu, Yuxin, Wang, Yan, Hao, Xuezhi, Zhu, Yixiang, Hu, Xingsheng, Wang, Hongyu, Liu, Peng, Lin, Lin, Wang, Zhijie, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275823/
https://www.ncbi.nlm.nih.gov/pubmed/30324773
http://dx.doi.org/10.1111/1759-7714.12886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275823/
https://www.ncbi.nlm.nih.gov/pubmed/30324773
http://dx.doi.org/10.1111/1759-7714.12886

Ejemplares similares